Phase III trial of assessment of myocardial perfusion using PET imaging of flurpiridaz F18 injection in patients with suspected or known coronary artery disease

Trial Profile

Phase III trial of assessment of myocardial perfusion using PET imaging of flurpiridaz F18 injection in patients with suspected or known coronary artery disease

Planning
Phase of Trial: Phase III

Latest Information Update: 06 May 2015

At a glance

  • Drugs Flurpiridaz F 18 (Primary)
  • Indications Coronary artery disease
  • Focus Diagnostic use
  • Sponsors Lantheus Medical Imaging
  • Most Recent Events

    • 06 May 2015 New trial record
    • 04 May 2015 The US FDA has granted a Special Protocol Assessment in connection with this new second phase III study, according to a according to a Lantheus Medical Imaging media release.
    • 04 May 2015 The first phase III trial investigating the diagnostic efficacy of flurpiridaz F-18 PET myocardial perfusion imaging has been completed, and a second one was withdrawn prior to enrolment. Based on results of the first trial, Lantheus will conduct this new second phase III trial with a redesigned protocol and different primary endpoints, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top